Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Arrayit Corporation
  6. News
  7. Summary
    ARYC   US04269N1072

ARRAYIT CORPORATION

(ARYC)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arrayit Corporation Subsidiary Avant Diagnostics, Inc. Acquired by American Liberty Petroleum Corporation

12/31/2014 | 09:01am EST

SUNNYVALE, Calif., Dec. 31, 2014 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCQB:ARYC) announces that its subsidiary Avant Diagnostics, Inc., a medical technology company developing cutting edge medical diagnostic tests, has been acquired by American Liberty Petroleum Corporation (OTCBB:OREO). The board of directors and a majority of shareholders of American Liberty Petroleum Corporation have authorized a number of corporate actions in order to complete the acquisition, including a reverse split, a name change, authorization of Preferred Stock, and filing the required SEC disclosure statements. Upon the effectiveness of these corporate actions, Gregg Linn, Avant's CFO, will join the board of directors of the company as CEO and President.

In cooperation with Arrayit Corporation and DOCRO, Avant Diagnostics, Inc. is pursuing FDA approval of the market's first large panel biomarker monitoring and screening test for ovarian cancer. OvaDx® is an advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.

Safe Harbor

We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2014.

CONTACT: Investor Contact
         
         Investor Relations
         Arrayit Corporation
         investorrelations@arrayit.com
         
         Gregg Linn, CFO
         Avant Diagnostics, Inc.
         investors@avantdiagnostics.com

Arrayit Logo


ę GlobeNewswire 2014
All news about ARRAYIT CORPORATION
2020COVID-19 : Weekly Oversight And Enforcement Report—Week Of October 1, 2020
AQ
2020ARRAYIT : SEC Charges Top Executive of California Microcap Company for Misleading Claims C..
AQ
2020ARRAYIT : DOJ Announces Criminal Charges Against Lab Executive Accused Of Fraudulently Pro..
AQ
2020ARRAYIT : California tech CEO charged in coronavirus test fraud case
AQ
2019Arrayit Corporation Approved as New Medicare Part B Healthcare Provider for Allergy Tes..
GL
2019Arrayit Corporation Receives Approval as New Medicare Part B Healthcare Provider for Al..
CI
2019Arrayit Corporation Announces Global Expansion of Finger Stick Health and Wellness Test..
GL
2019Arrayit Corporation Announces Global Expansion of Finger Stick Health and Wellness Test..
CI
2019Arrayit Corporation Announces Allergy Testing Services Network Expansion to Multiple Cl..
GL
2019Arrayit Corporation Announces Allergy Testing Services Network Expansion to Multiple Cl..
CI
More news
Chart ARRAYIT CORPORATION
Duration : Period :
Arrayit Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Rene A. Schena Chairman & Chief Executive Officer
Mark Schena President, Secretary & Director
Todd J. Martinsky Director, Chief Technology Officer & EVP
Sector and Competitors
1st jan.Capi. (M$)
ARRAYIT CORPORATION-85.71%0
SARTORIUS AG49.57%42 253
BIOTAGE AB (PUBL)89.21%1 908
REVENIO GROUP OYJ8.55%1 635
VAREX IMAGING CORPORATION74.16%1 146
CELLAVISION AB (PUBL)14.01%918